-
Je něco špatně v tomto záznamu ?
Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL)
R. Nedomova, T. Papajik, V. Prochazka, K. Indrak, M. Jarosova
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NT11103
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
23132512
DOI
10.5507/bp.2012.085
Knihovny.cz E-zdroje
- MeSH
- chromozomální aberace * MeSH
- difúzní velkobuněčný B-lymfom klasifikace genetika MeSH
- dospělí MeSH
- geny bcl-2 genetika MeSH
- lidé MeSH
- nádorová transformace buněk genetika MeSH
- nádory mediastina genetika MeSH
- prognóza MeSH
- protoonkogenní proteiny c-bcl-6 genetika MeSH
- stanovení celkové genové exprese MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) accounts for up to 40% of all non-Hodgkin's lymphomas diagnosed in the western hemisphere. Determination of the gene expression profile has confirmed the physiological heterogeneity of the disease and defined three molecular prognostic subgroups - germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL) - with different gene expression and prognosis. METHODS AND RESULTS: This review covers current knowledge on the most frequent recurrent cytogenetic and molecular cytogenetic aberrations in molecular DLBCL subgroups. CONCLUSIONS: Cytogenetic and molecular cytogenetic techniques used to determine nonrandom chromosomal aberrations in patients with DLBCL have revealed the incidence of frequent cytogenetic aberrations in the subgroups reported, suggesting their potential use for more accurate prognostic stratification of DLBCL, contributing to personalized selection of the most effective therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14049951
- 003
- CZ-PrNML
- 005
- 20170327132733.0
- 007
- ta
- 008
- 140325s2013 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2012.085 $2 doi
- 035 __
- $a (PubMed)23132512
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Nedomová, Radka $7 xx0199218 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc
- 245 10
- $a Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL) / $c R. Nedomova, T. Papajik, V. Prochazka, K. Indrak, M. Jarosova
- 520 9_
- $a BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) accounts for up to 40% of all non-Hodgkin's lymphomas diagnosed in the western hemisphere. Determination of the gene expression profile has confirmed the physiological heterogeneity of the disease and defined three molecular prognostic subgroups - germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL) - with different gene expression and prognosis. METHODS AND RESULTS: This review covers current knowledge on the most frequent recurrent cytogenetic and molecular cytogenetic aberrations in molecular DLBCL subgroups. CONCLUSIONS: Cytogenetic and molecular cytogenetic techniques used to determine nonrandom chromosomal aberrations in patients with DLBCL have revealed the incidence of frequent cytogenetic aberrations in the subgroups reported, suggesting their potential use for more accurate prognostic stratification of DLBCL, contributing to personalized selection of the most effective therapy.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a nádorová transformace buněk $x genetika $7 D002471
- 650 12
- $a chromozomální aberace $7 D002869
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a geny bcl-2 $x genetika $7 D019254
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a difúzní velkobuněčný B-lymfom $x klasifikace $x genetika $7 D016403
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádory mediastina $x genetika $7 D008479
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a protoonkogenní proteiny c-bcl-6 $x genetika $7 D051560
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Papajík, Tomáš, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc $d 1967- $7 xx0060566
- 700 1_
- $a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc $7 xx0143822
- 700 1_
- $a Indrák, Karel, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc $d 1947- $7 jn20000401162
- 700 1_
- $a Jarošová, Marie, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc $d 1950- $7 xx0053403
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 157, č. 3 (2013), s. 239-247
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20140325 $b ABA008
- 991 __
- $a 20170327133012 $b ABA008
- 999 __
- $a ok $b bmc $g 1017423 $s 848521
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 157 $c 3 $d 239-247 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- GRA __
- $a NT11103 $p MZ0
- LZP __
- $b NLK111 $a Pubmed-20140325
